Trial reportClinical pharmacology and therapeutics2017
Antiretroviral Therapy With Efavirenz Accentuates Pregnancy-Associated Reduction of Dihydroartemisinin-Piperaquine Exposure During Malaria Chemoprevention.
Registry-linked trialOpen access · greenAbstract readRandomized Controlled Trial
In one paragraph
Trial report in Clinical pharmacology and therapeutics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02282293 (Reducing the Burden of Malaria in HIV-Infected Pregnant Women and Their HIV-Exposed Children), which is not on this map. Cited by 30 papers.
0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed
6.0field-weighted citation impact, top 4% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Reducing the Burden of Malaria in HIV-Infected Pregnant Women and Their HIV-Exposed Children (PROMOTE Birth Cohort 2)
Who cites it
30 citing papers in PubMed, 42 citations in OpenAlex.
- Drug-Drug Interaction Between Dihydroartemisinin-Piperaquine and Sulfadoxine-Pyrimethamine During Malaria Chemoprevention in Pregnant Women.Clinical pharmacology and therapeutics · 2025Trial
- Chemoprevention for malaria with monthly intermittent preventive treatment with dihydroartemisinin-piperaquine in pregnant women living with HIV on daily co-trimoxazole in Kenya and Malawi: a randomised, double-blind, placebo-controlled trial.Lancet (London, England) · 2024Trial
- Impact of Dolutegravir-Based Antiretroviral Therapy on Piperaquine Exposure following Dihydroartemisinin-Piperaquine Intermittent Preventive Treatment of Malaria in Pregnant Women Living with HIV.Antimicrobial agents and chemotherapy · 2022Trial
- Piperaquine-Induced QTc Prolongation Decreases With Repeated Monthly Dihydroartemisinin-Piperaquine Dosing in Pregnant Ugandan Women.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2022Trial
- Effect of dihydroartemisinin/piperaquine for malaria intermittent preventive treatment on dolutegravir exposure in pregnant women living with HIV.The Journal of antimicrobial chemotherapy · 2022Trial
- Randomized Controlled Trial of the Electrocardiographic Effects of Four Antimalarials for Pregnant Women with Uncomplicated Malaria on the Thailand-Myanmar Border.Antimicrobial agents and chemotherapy · 2021Trial
- Trial
- Modeling Prevention of Malaria and Selection of Drug Resistance with Different Dosing Schedules of Dihydroartemisinin-Piperaquine Preventive Therapy during Pregnancy in Uganda.Antimicrobial agents and chemotherapy · 2019Trial
- Intermittent Preventive Treatment for Malaria in Pregnancy: Optimization of Target Concentrations of Dihydroartemisinin-Piperaquine.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2018Trial
- Pharmacokinetics of Piperaquine and Safety Profile of Dihydroartemisinin-Piperaquine Coadministered with Antiretroviral Therapy in Malaria-Uninfected HIV-Positive Malawian Adults.Antimicrobial agents and chemotherapy · 2018Trial
- Impact of Dolutegravir-, Lopinavir/Ritonavir-, and Efavirenz-Based Antiretrovirals on Piperaquine Pharmacokinetics in Ugandan Children Living with HIV.Clinical pharmacology and therapeutics · 2026Article
- Development and validation of UHPLC-MS/MS methods for determination of piperaquine in quantitative dried blood samples and microvolume plasma samples.Journal of chromatography. B, Analytical technologies in the biomedical and life sciences · 2026Article
- Pharmacokinetic Adaptations in Pregnancy: Implications for Optimizing Antiretroviral Therapy in HIV-Positive Women.Pharmaceutics · 2025Review
- Evaluating the Safety and Efficacy of Malaria Preventive Measures in Pregnant Women with a Focus on HIV Status: A Systematic Review and Network Meta-Analysis.Journal of clinical medicine · 2025Review
- A Comprehensive Review on the Pharmacokinetics and Bioanalysis of Piperaquine.Current drug metabolism · 2025Review
- Pharmacokinetics of piperaquine and its association with intermittent malaria preventive therapy outcomes during pregnancy.BMC pharmacology & toxicology · 2024Article
- Efavirenz-Based Antiretroviral Therapy but Not Pregnancy Increased Unbound Piperaquine Exposure in Women during Malaria Chemoprevention.Antimicrobial agents and chemotherapy · 2023Article
- Determination of unbound piperaquine in human plasma by ultra-high performance liquid chromatography tandem mass spectrometry.Journal of chromatography open · 2022Article
- Magnitude of Drug-Drug Interactions in Special Populations.Pharmaceutics · 2022Review
- Malaria PK/PD and the Role Pharmacometrics Can Play in the Global Health Arena: Malaria Treatment Regimens for Vulnerable Populations.Clinical pharmacology and therapeutics · 2021Review
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
14 authors at 3 institutions in 2 countries.
R KajubiInfectious Disease Research Collaboration, Makerere University College of Health Sciences, Kampala, Uganda.
L HuangDepartment of Clinical Pharmacy, University of California, San Francisco, San Francisco General Hospital, San Francisco, California, USA.
P JagannathanDepartment of Medicine, University of California, San Francisco, San Francisco General Hospital, San Francisco, California, USA.
N ChamankhahDepartment of Clinical Pharmacy, University of California, San Francisco, San Francisco General Hospital, San Francisco, California, USA.
M WereInfectious Disease Research Collaboration, Makerere University College of Health Sciences, Kampala, Uganda.
T RuelDepartment of Pediatrics, University of California, San Francisco, San Francisco General Hospital, San Francisco, California, USA.
C A KossDepartment of Medicine, University of California, San Francisco, San Francisco General Hospital, San Francisco, California, USA.
A KakuruInfectious Disease Research Collaboration, Makerere University College of Health Sciences, Kampala, Uganda.
N MwebazaInfectious Disease Research Collaboration, Makerere University College of Health Sciences, Kampala, Uganda.
M KamyaInfectious Disease Research Collaboration, Makerere University College of Health Sciences, Kampala, Uganda.
D HavlirDepartment of Medicine, University of California, San Francisco, San Francisco General Hospital, San Francisco, California, USA.
G DorseyDepartment of Medicine, University of California, San Francisco, San Francisco General Hospital, San Francisco, California, USA.
P J RosenthalDepartment of Medicine, University of California, San Francisco, San Francisco General Hospital, San Francisco, California, USA.
F T AweekaDepartment of Clinical Pharmacy, University of California, San Francisco, San Francisco General Hospital, San Francisco, California, USA.
University of California, San Francisco · USMakerere University · UGSan Francisco General Hospital · US
Funding
Virology CoreP30AI027763 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI STEVEN Grant DEEKS · 1988 to 2026
$93.6MSan Francisco Vaccine and Prevention UnitUM1AI069496 · NIAID · PUBLIC HEALTH FOUNDATION ENTERPRISES · PI Susan Buchbinder, Diane V Havlir · 2012 to 2026
$30.5MThe immunologic consequences of prenatal exposure to malariaP01HD059454 · NICHD · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI HAVLIR, DIANE V · 2008 to 2017
$22.6MUCSF/Kaiser-DOR Program for Developing Independent Women's Health ResearchersK12HD052163 · NICHD · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI ADLER, NANCY E, BRINDIS, CLAIRE D. · 2005 to 2023
$9.3MPharmacological insights into antimalarial exposure, clinical outcomes, and drug resistance in AfricaR01AI117001 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI AWEEKA, FRANCESCA T., ROSENTHAL, PHILIP JON · 2015 to 2024
$7.1MTraining in HIV Translational ResearchT32AI060530 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Diane V Havlir · 2005 to 2026
$6.4MImmunologic Consequences of Highly Effective Antimalarial ChemopreventionK23AI100949 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI JAGANNATHAN, PRASANNA · 2012 to 2016
$657kNIAID NIH HHS K23 AI100949NIAID NIH HHS P30 AI027763NIAID NIH HHS R01 AI117001NIAID NIH HHS T32 AI060530NIAID NIH HHS UM1 AI069496NICHD NIH HHS K12 HD052163NICHD NIH HHS P01 HD059454
Abstract
Dihydroartemisinin (DHA)-piperaquine is promising for malaria chemoprevention in pregnancy. We assessed the impacts of pregnancy and efavirenz-based antiretroviral therapy on exposure to DHA and piperaquine in pregnant Ugandan women. Intensive sampling was performed at 28 weeks gestation in 31 HIV-uninfected pregnant women, in 27 HIV-infected pregnant women receiving efavirenz, and in 30 HIV-uninfected nonpregnant women. DHA peak concentration and area under the concentration time curve (AUC
Indexed as
AdolescentAdultAlkynesAntimalarialsArea Under CurveArtemisininsBenzoxazinesChemopreventionCyclopropanesDose-Response Relationship, DrugDrug CombinationsDrug InteractionsFemaleHIV InfectionsHumansMalariaAlkynesAntimalarialsArtemisininsartenimolBenzoxazinesCyclopropanesDrug CombinationsefavirenzpiperaquinePiperazinesQuinolinesReverse Transcriptase Inhibitors
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
NCT02282293ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.